The Heparin-Antithrombin Product: A Novel Value for Pediatric Extracorporeal Anticoagulation

Area of Science:

• Pediatric critical care medicine
• Hematology
• Biomedical engineering

Background:

• Hematologic complications are significant risks for patients requiring extracorporeal membrane oxygenation (ECMO).
• Current strategies for monitoring anticoagulation in pediatric ECMO patients lack consensus.
• Effective anticoagulation management is crucial to prevent thrombosis and bleeding during ECMO.

Purpose of the Study:

• To evaluate a novel anticoagulation measurement, the heparin-antithrombin product (HAP), in children supported by ECMO.
• To compare the HAP value's correlation with anti-Xa levels against traditional measures like heparin dose, antithrombin III (AT) level, and activated clotting time (ACT).

Main Methods:

• A single-center observational study included 128 pediatric patients on ECMO from 2015 to 2020.
• The HAP value was calculated by multiplying the unfractionated heparin dose by the patient's AT level.
• Linear correlation and decision tree methods were used to compare HAP with heparin dose, AT, ACT, and anti-Xa values.

Main Results:

• The HAP value demonstrated a stronger correlation with anti-Xa levels compared to heparin dose, AT level, and ACT.
• This correlation was particularly notable in the neonatal population (r = .7).
• Regression tree and random forest models identified HAP as the most influential predictor of anti-Xa levels.

Conclusions:

• The heparin-antithrombin product (HAP) shows promise as a superior measure for anticoagulation monitoring in pediatric ECMO patients.
• Further research is warranted to validate the clinical effectiveness of HAP in guiding anticoagulation therapy.
• Improved anticoagulation monitoring could potentially reduce morbidity and mortality associated with ECMO support.